{
  "abstract": "Introduction Systemic sclerosis (SSc) is a heterogeneous immune-mediated disease characterized by vasculopathy and fibrosis. Nailfold videocapillaroscopy (NVC) is a validated non-invasive tool to assess microvascular involvement. Distinct autoantibodies, such as anti-centromere (ACA) and anti-topoisomerase I (ATA), are associated with different clinical phenotypes, but their correlation with capillaroscopic patterns remains uncertain.Material and Methods Objectives: To compare capillaroscopic features between adult SSc patients positive for ACA and those positive for ATA.Methods We performed a retrospective observational study using data from the CAPillaroscopy Registry Almada-Seixal (CAPRAS), including NVCs from 2014–2024. Eligible patients were adult aged 18 years or older, had confirmed SSc (limited, diffuse, or sine), and were positive for ACA or ATA. Patients with incomplete demographic or clinical data were excluded. Capillaroscopic findings were evaluated using a Dino-Lite CapillaryScope 200 Pro. Categorical variables were compared with chi-squared or Fisher’s exact test, and continuous variables with the Mann-Whitney U test (p < 0.05).Results Eighty-seven patients were included: 68 (78.2%) ACA positive and 19 (21.8%) ATA positive. ACA patients were older (median 62.5 [IQR 51.9–73.2] vs. 48 [IQR 30–67] years; p=0.032), more often female (92.6% vs. 84.2%) and Caucasian (95.6% vs. 84.2%), though the latter differences were not significant. Raynaud’s phenomenon was highly prevalent in both groups (97.1% ACA vs. 94.7% ATA).Onset of Raynaud’s was later in ACA patients (median 54.7 years [IQR 42.2–72.5]) compared with ATA (48.0 years [IQR 30.0–67.0]). Duration of Raynaud’s was longer in ACA patients (6.8 vs. 4.7 years), though not statistically significant.Capillaroscopic patterns were comparable: the active scleroderma pattern was most frequent (38.2% ACA, 36.8% ATA). No significant differences in microvascular findings or capillaroscopic patterns were observed between antibody subtypes.Conclusions In this cohort, ACA and ATA positive SSc patients exhibited largely similar demographic, clinical, and capillaroscopic features. Significant differences were limited to older age and later Raynaud’s onset in ACA patients, consistent with a slower disease course described in the literature. Despite frequent abnormalities, capillaroscopic findings did not differ between antibody groups, suggesting that autoantibody subtype alone may not determine microvascular involvement. However, timing of capillaroscopy relative to Raynaud’s onset may confound results, as longer disease duration in ACA patients could mask early differences. The small ATA subgroup also limited statistical power to detect subtle variations.Abstract P.192 Table 1Description of demographic, clinical, and capillaroscopic characteristics of patients with systemic sclerosis. Comparison between anti-centromere and anti-topoisomerase I positive groups",
  "authors": [
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Susana Matias"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Tómas Novais"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Rodrigo Rei"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Catarina Abreu"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Vanessa Fraga"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Alice Castro"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Ana Cordeiro"
    },
    {
      "affiliations": [
        "Hospital Garcia de Orta, Almada, Portugal"
      ],
      "name": "Maria José Santos"
    }
  ],
  "title": "P.192 Capillaroscopic features in systemic sclerosis: a comparative study of patients positive for anti-centromere and for anti-topoisomerase I antibodies from the CAPRAS registry",
  "uid": "34d85b77-cb2a-56dd-9739-3621723de9c3"
}